Clonal germinal center B cells function as a niche for T-cell lymphoma.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
03 11 2022
03 11 2022
Historique:
accepted:
13
07
2022
received:
07
01
2022
pubmed:
4
8
2022
medline:
8
11
2022
entrez:
3
8
2022
Statut:
ppublish
Résumé
Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox × G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre × Tet2flox/flox × G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40-Cd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40-CD40LG axis.
Identifiants
pubmed: 35921527
pii: S0006-4971(22)00975-2
doi: 10.1182/blood.2022015451
pmc: PMC10653021
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1937-1950Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Science. 2014 Aug 29;345(6200):1058-62
pubmed: 25170154
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32603407
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Cancer Sci. 2021 Dec;112(12):4931-4943
pubmed: 34657351
Br J Haematol. 2010 Mar;148(5):673-89
pubmed: 19961485
Blood. 1992 Apr 1;79(7):1789-95
pubmed: 1373088
Br J Haematol. 2007 Jul;138(1):44-53
pubmed: 17555446
Immunity. 2013 May 23;38(5):918-29
pubmed: 23684984
Immunity. 2001 Nov;15(5):763-74
pubmed: 11728338
Immunity. 2016 Jan 19;44(1):194-206
pubmed: 26795250
Nature. 2018 Nov;563(7731):347-353
pubmed: 30429548
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
Haematologica. 2012 Oct;97(10):1594-602
pubmed: 22371178
Nature. 2021 Jan;589(7841):299-305
pubmed: 33299181
Nature. 2015 Jan 8;517(7533):214-8
pubmed: 25317561
Nat Methods. 2015 May;12(5):380-1
pubmed: 25924071
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
Science. 2007 Jan 26;315(5811):528-31
pubmed: 17185562
Blood Cancer J. 2017 Jan 6;7(1):e516
pubmed: 28157189
Cancer Discov. 2018 Dec;8(12):1632-1653
pubmed: 30274972
Science. 1995 Sep 8;269(5229):1427-9
pubmed: 7660125
Blood Adv. 2020 Mar 10;4(5):868-879
pubmed: 32130407
Nature. 2021 Mar;591(7850):458-463
pubmed: 33536617
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Commun. 2017 May 05;8:15081
pubmed: 28474673
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Blood. 2007 Jun 1;109(11):4952-63
pubmed: 17284527
Immunity. 2017 Aug 15;47(2):284-297.e5
pubmed: 28813659
Cancer Cell. 2011 Jul 12;20(1):25-38
pubmed: 21723201
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Leukemia. 2022 Jan;36(1):165-176
pubmed: 34230608
Cancer Res. 2020 May 1;80(9):1875-1884
pubmed: 32107212
J Exp Med. 2001 Oct 1;194(7):927-40
pubmed: 11581315
PLoS One. 2013 Jun 25;8(6):e64536
pubmed: 23825522
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Leukemia. 2018 Mar;32(3):694-702
pubmed: 28832024
Nature. 2021 Apr;592(7852):133-137
pubmed: 33597749